Proactive news headlines including Spenda Ltd, Island Pharmaceuticals, Tempus Resources and Paradigm Biopharmaceuticals

Sydney, Dec. 28, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

• Spenda Ltd (ASX:SPX) and Fiserv have entered into a two-year Payment Facilitator agreement, whereby Fiserv will provide direct merchant facilities to Spenda’s customers. Click here
• Island Pharmaceuticals Ltd (ASX:ILA), an Australian mid-clinical stage antiviral drug development company, has submitted an Investigational New Drug (IND) application for the ISLA-101 Phase 2a PEACH clinical trial. Click here
• Tempus Resources Ltd (ASX:TMR, TSX-V:TMRR) has boosted its finances to the tune of C$680,100 (~A$747,939) after completing a non-brokered private placement. Click here
• Paradigm Biopharmaceuticals Ltd (ASX:PAR) announced today that the first safety review meeting of the Data Monitoring Committee (DMC) for the pivotal PARA_OA_002 clinical trial was conducted on December 20. Click here

About Proactive

• Proactive is a unique tech-enabled platform providing companies globally with a comprehensive investor engagement solution across their business lifecycle.
• With six offices on three continents, Proactive works with innovative growth companies quoted on the world’s major stock exchanges, helping executives to engage intelligently with investors.
• In 2020, Proactive featured in 809 million search results, our content was viewed over 165 million times and our readers spent over 10 million hours on our websites. Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006. 

For more information on how Proactive can help you make a difference, email us at [email protected].